Table 2. Ongoing therapeutic modulation coronary imaging studies.
| Study | Disease cohort and enrolment estimate | Intervention | Modality | Primary end-point | Important secondary end-point(s) | Estimated study completion date |
|---|---|---|---|---|---|---|
| Traditional therapy | ||||||
| STAFENO, Han et al. (NCT02232360) | Intermediate CAD, n=106 | Rosuvastatin 10 mg/day plus fenofibrate 160 mg/day vs. rosuvastatin 10 mg/day for 52 weeks | VH-IVUS | Percent and absolute changes of Necrotic Core volume in non-culprit intermediate lesion from baseline to week 52 | Change in the presence of TCFA | December 2020 |
| ROSUZET-IVUS, Hahn et al. (NCT03169985) | Symptomatic CAD, n=280 | Rosuvastatin 10 mg/day plus ezetimibe 10 mg/day vs. rosuvastatin 20 mg/day for 52 weeks | IVUS, OCT | Change in PAV in non-culprit lesion by IVUS from baseline to week 52 | Change in normalised TAV by IVUS and minimum FCT by OCT | December 2023 |
| PCSK-9 inhibitors | ||||||
| ANTARES, Otake et al. (NCT03529253) | Symptomatic CAD who underwent PCI, n=30 | Alirocumab SC injections fortnightly plus rosuvastatin 10 mg/day vs. rosuvastatin 10 mg/day for 36 weeks | NIRS | maxLCBI (4 mm) in non-culprit lesion from baseline to week 36 | Change in amount of LCBI | September 2020 |
| HUYGENS, Amgen (NCT03570697) | NSTE-ACS, n=150 | Evolocumab SC injection monthly vs. placebo for 48 weeks | OCT | Absolute change in minimum FCT in matched segment of artery from baseline to week 50 | Percentage change in FCT | December 2020 |
| PACMAN-AMI, Räber et al. (NCT03067844) | ACS who underwent PCI, n=220 | Alirocumab SC injection fortnightly vs. placebo for 50 weeks | IVUS, OCT, NIRS | Change in PAV in non-culprit lesion by IVUS from baseline to week 52 | Change in LCBI by NIRS and minimum FCT by OCT | March 2021 |
| ALTAIR, Otake et al. (NCT03552432) | Symptomatic CAD who underwent PCI, n=24 | Alirocumab SC injection fortnightly with rosuvastatin 10 mg/day vs. rosuvastatin 10 mg/day for 36 weeks | OCT | Absolute change in minimum FCT in non-culprit lesion from baseline to week 36 | Percentage change in FCT and plaque macrophage grade | September 2021 |
| Anti-inflammation | ||||||
| COCOMO-ACS, Psaltis et al. (ACTRN 12618000809235) | NSTEMI, n=82 | Colchicine 0.5 mg/day vs. placebo for 52 weeks | OCT | Percentage change in minimum FCT in non-culprit lesion from baseline to week 52 | Change in plaque lipid pool size and macrophage content | June 2021 |
ACS, acute coronary syndrome, CAD, coronary artery disease, FCT, fibrous cap thickness; LCBI, lipid-core burden index; NSTE-ACS, non-ST-elevation acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; PAV, percent atheroma volume; PCSK-9, proprotein convertase subtilisin/kexin type 9, SC, subcutaneous.